Hospice Care and Medications: Related vs. Unrelated to the Terminal Illness

When a patient elects the Medicare Hospice Benefit, one of the most operationally sensitive and frequently misunderstood areas of care is medication coverage. Families often assume that hospice automatically covers all prescriptions the patient was taking prior to admission. Clinicians, meanwhile, must navigate CMS expectations that are both clinically nuanced and financially consequential.

The governing principle under Medicare is straightforward in concept but complex in application: hospice covers medications that are related to the patient’s terminal diagnosis and related conditions, as well as those that contribute directly to symptom control and comfort. Everything else may be considered unrelated—and therefore potentially billable under another benefit such as Medicare Part D.

Understanding and correctly applying this distinction is essential for three reasons:

• Ensuring patients receive appropriate symptom management without interruption

• Maintaining compliance with CMS Hospice Conditions of Participation

• Preventing claim denials, audit findings, and financial liability for the agency

This article provides a detailed regulatory and clinical framework for differentiating related versus unrelated medications, along with documentation expectations, interdisciplinary processes, and practical decision-making strategies.

CMS Framework: The “Relatedness” Standard in Hospice

Medicare does not define hospice medication coverage by diagnosis alone or by prescriber intent. Instead, coverage is determined by whether a medication is considered related to the terminal illness and related conditions under the hospice benefit.

This standard is grounded in the broader Medicare Hospice Conditions of Participation under 42 CFR Part 418, which establish that hospice assumes responsibility for services and items necessary for palliation and management of a terminal illness and related conditions.

In practical terms, CMS expects that:

• The hospice assumes financial responsibility for medications that contribute to comfort or symptom management

• Medications tied to the trajectory or complications of the terminal disease are included in the hospice bundle

• Only medications with no reasonable relationship to the terminal condition may be excluded

Importantly, CMS guidance and audit practice create a presumption of relatedness. In other words, unless the hospice can clearly justify otherwise, medications are assumed to be related.

The Clinical Principle: Whole-Person Impact of Terminal Illness

One of the most important conceptual foundations in hospice medication management is the recognition that terminal illness is not isolated to a single organ system. It affects multiple physiological systems, often exacerbating chronic comorbidities.

For example:

• A patient with end-stage congestive heart failure (CHF) may also have diabetes, hypertension, and chronic kidney disease

• A patient with metastatic cancer may experience COPD, depression, and cachexia

• A patient with advanced dementia may also have seizure disorder, hypertension, and dysphagia

Even when comorbidities predate hospice enrollment, their treatment frequently affects:

• Symptom burden

• Functional status

• Disease progression

• Patient comfort

As a result, medications addressing these conditions are often considered part of the hospice plan of care when they contribute to palliation or stabilization.

What Are “Related” Medications in Hospice?

Related medications are those hospice is responsible for covering under the Medicare hospice benefit because they contribute to comfort, symptom control, or management of conditions directly impacting the terminal illness.

These include three primary categories:

1. Medications Treating the Terminal Illness

These are drugs directly targeting the disease process or its primary symptoms.

Examples include:

• Opioids (e.g., morphine) for cancer pain or dyspnea

• Diuretics (e.g., furosemide) for fluid overload in end-stage heart failure

• Bronchodilators in advanced pulmonary disease

• Anticonvulsants in brain metastases or seizure-related terminal conditions

2. Medications for Related Conditions

These treat comorbidities that directly influence the terminal disease trajectory or symptom burden.

Examples include:

• Antihypertensives in CHF where blood pressure control impacts cardiac stability

• Insulin in a diabetic patient whose glucose instability affects wound healing or cognition

• Antibiotics for recurrent infections contributing to decline in end-stage disease

3. Symptom Management and Comfort Medications

These are palliative in nature and are central to hospice philosophy.

Examples include:

• Anti-nausea medications (e.g., ondansetron)

• Laxatives for opioid-induced constipation

• Anxiolytics for terminal agitation

• Antipsychotics for delirium

• Steroids for appetite stimulation or inflammation control

These medications are almost always considered hospice-covered when they address active symptom burden.

What Are “Unrelated” Medications?

Unrelated medications are those that do not contribute meaningfully to symptom management, comfort, or the trajectory of the terminal illness.

These are typically:

• Preventive therapies

• Long-term risk reduction medications

• Drugs for unrelated chronic conditions not affecting end-of-life care

Common Examples of Unrelated Medications

• Statins for long-term cardiovascular risk prevention

• Vitamins and supplements without palliative benefit

• Acne treatments or dermatologic maintenance medications

• Antihypertensives used solely for long-term prevention in a patient whose blood pressure is no longer clinically relevant

• Osteoporosis medications intended for long-term fracture prevention in actively declining patients

These medications may be billed under Medicare Part D or other insurance, depending on coverage rules and hospice coordination.

The Critical Role of Clinical Judgment

Medication classification is not purely algorithmic. It requires interdisciplinary clinical judgment guided by CMS expectations and patient-specific context.

A medication considered unrelated at one stage may become related later in the disease trajectory. For example:

• An antidepressant initially deemed preventive may later be essential for terminal anxiety or existential distress

• A cardiac medication may transition from preventive use to symptom stabilization in advanced CHF

Because of this fluidity, CMS expects ongoing reassessment rather than static classification.

Documentation Requirements: CMS Compliance Standard

When a hospice determines a medication is unrelated, documentation must be:

• Clear

• Clinically justified

• Consistent with the plan of care

• Communicated to the patient and family

At minimum, documentation should include:

• Terminal diagnosis

• Medication name and indication

• Clinical rationale for unrelated classification

• Explanation of lack of impact on symptom management or disease trajectory

• Education provided to patient/family regarding coverage responsibility

Example documentation:

“Patient admitted with end-stage COPD. Simvastatin deemed unrelated as it is not contributing to symptom management or quality of life in the hospice context. Medication coverage discussed with family; instructed that drug will remain under Part D benefit.”

Incomplete or vague documentation is a common trigger for audit findings and survey deficiencies.

The Interdisciplinary Group (IDG) Role

The Interdisciplinary Group is central to medication management in hospice care. CMS expects medication decisions to be made collaboratively, not unilaterally.

The IDG typically includes:

• RN case managers

• Medical director

• Social workers

• Pharmacists (when available)

• Hospice aides and therapists (as appropriate)

The IDG is responsible for:

• Reviewing full medication profiles at admission

• Evaluating ongoing medication necessity at each recertification

• Determining related vs. unrelated status

• Documenting rationale for decisions

• Communicating determinations to prescribing providers

This collaborative process ensures consistency and reduces regulatory risk.

Communication with Patients and Families

Medication coverage decisions can be a major source of confusion and emotional stress for families.

Effective hospice communication should:

• Explain that coverage is based on comfort and terminal illness relevance

• Clarify why certain medications may no longer be covered

• Provide written medication lists identifying covered vs. non-covered drugs

• Assist with coordination through Medicare Part D or other insurers when appropriate

Clear communication reduces complaints, improves trust, and prevents misunderstandings about financial responsibility.

Practical Decision-Making Framework

Clinicians can use a structured approach when evaluating medication status:

1. Symptom Relevance

Does the medication treat a symptom of the terminal illness?

2. Impact on Comfort

Would discontinuation worsen comfort, pain, or quality of life?

3. Disease Trajectory Influence

Does the medication meaningfully impact the progression or complications of the terminal condition?

4. Preventive vs. Palliative Purpose

Is the medication primarily preventive rather than symptom-directed?

5. Interdisciplinary Consensus

Does the IDG agree on classification?

This structured approach improves consistency and audit defensibility.

Why Accurate Classification Matters

Correctly distinguishing related vs. unrelated medications is essential for multiple reasons:

Patient Impact

• Prevents interruption of necessary symptom control medications

• Avoids confusion about coverage and financial responsibility

• Ensures continuity of comfort-focused care

Regulatory Compliance

• Aligns with CMS hospice expectations under 42 CFR Part 418

• Reduces risk of audit findings or ADR denials

• Supports defensible documentation during surveys

Financial Integrity

• Prevents inappropriate billing of non-covered drugs

• Reduces claim denials and repayment risk

• Ensures proper coordination with Part D and other payers

Clinical Efficiency

• Reduces polypharmacy at end of life

• Focuses care on symptom management rather than preventive treatment

• Enhances clarity in interdisciplinary care planning

Conclusion

The distinction between related and unrelated medications in hospice is one of the most clinically nuanced and operationally important aspects of Medicare hospice compliance. While CMS establishes a clear principle—that hospice covers medications related to the terminal illness and its symptoms—the application of that principle requires careful clinical judgment, interdisciplinary collaboration, and precise documentation.

In practice, most medications in hospice are considered related unless a clear, well-documented rationale supports exclusion. Agencies that adopt structured decision-making frameworks, maintain robust IDG processes, and prioritize clear communication with families are best positioned to remain compliant while delivering high-quality, patient-centered care.

Ultimately, effective medication management in hospice is not just about regulatory adherence—it is about ensuring that patients at the end of life receive appropriate, compassionate, and uninterrupted symptom relief.

References

1. Centers for Medicare & Medicaid Services (CMS). “42 CFR Part 418 – Hospice Conditions of Participation.” Available at: Electronic Code of Federal Regulations

2. Centers for Medicare & Medicaid Services (CMS). “Medicare Benefit Policy Manual, Chapter 9: Coverage of Hospice Services.” Available at: CMS Manuals

3. Centers for Medicare & Medicaid Services (CMS). “Hospice Care Coverage Guidelines and Relatedness Determinations.” Available at: CMS Hospice Guidance

4. National Hospice and Palliative Care Organization (NHPCO). “Hospice Medication Management Resources.” Available at: NHPCO Official Website

5. Agency for Healthcare Research and Quality (AHRQ). “Medication Safety in Serious Illness and End-of-Life Care.” Available at: AHRQ Patient Safety Resources